title: Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor.
abstract: We determined the effects of etanercept on the serum concentrations of neuropeptides in RA patients. In a total of 11 patients who had been injected with etanercept, the serum levels of substance P, calcitonin gene-related peptide (CGRP), and gastrin-releasing peptide (GRP) were analyzed. Average levels of serum substance P were significantly reduced from 1.53 to 0.62 ng/ml after the injection of etanercept. In the CGRP and GRP analyses, these average levels dropped from 1.57 and 0.51 ng/ml to 0.44 and 0.04 ng/ml, respectively. Etanercept appears to decrease substance P levels with an improvement in disease activities.
authors.affiliation: Department of Rehabilitation Sciences, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki 852-8520, Japan. origuchi@nagasaki-u.ac.jp
authors.forename: Tomoki
authors.initials: T
authors.lastname: Origuchi
authors.forename: Naoki
authors.initials: N
authors.lastname: Iwamoto
authors.forename: Shin-ya
authors.initials: SY
authors.lastname: Kawashiri
authors.forename: Keita
authors.initials: K
authors.lastname: Fujikawa
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Aramaki
authors.forename: Mami
authors.initials: M
authors.lastname: Tamai
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Arima
authors.forename: Hideki
authors.initials: H
authors.lastname: Nakamura
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamasaki
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ida
authors.forename: Atsushi
authors.initials: A
authors.lastname: Kawakami
authors.forename: Yukitaka
authors.initials: Y
authors.lastname: Ueki
authors.forename: Naoki
authors.initials: N
authors.lastname: Matsuoka
authors.forename: Munetoshi
authors.initials: M
authors.lastname: Nakashima
authors.forename: Akinari
authors.initials: A
authors.lastname: Mizokami
authors.forename: Yojiro
authors.initials: Y
authors.lastname: Kawabe
authors.forename: Masanobu
authors.initials: M
authors.lastname: Mine
authors.forename: Takaaki
authors.initials: T
authors.lastname: Fukuda
authors.forename: Katsumi
authors.initials: K
authors.lastname: Eguchi
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000378:metabolism*; D002097:C-Reactive Protein / Q000378:metabolism; D015740:Calcitonin Gene-Related Peptide / Q000097:blood; D000068800:Etanercept; D005260:Female; D019886:Gastrin-Releasing Peptide / Q000097:blood; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D013373:Substance P / Q000097:blood*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D013373:Substance P; D019886:Gastrin-Releasing Peptide; D002097:C-Reactive Protein; D015740:Calcitonin Gene-Related Peptide; D000068800:Etanercept